Dr George Vassiliou
George's research seeks to understand the genetic pathways involved in the pathogenesis of haematological cancers and help develop targeted anti-leukaemic therapies.
George is a Wellcome Trust Senior Clinical Fellow and heads the Haematological Cancer Genetics Group. His group is studying the pathogenesis and treatment of haematological malignancies with a particular focus on acute myeloid leukaemia and multiple myeloma. He is also a Consultant Haematologist at Addenbrooke's Hospital in Cambridge where he treats patients with these diseases.
Selected Publications
-
Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia.
Blood 2013;121;12;2289-300
PUBMED: 23327922; DOI: 10.1182/blood-2012-07-446120
-
A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice.
Leukemia 2013
PUBMED: 23478666; DOI: 10.1038/leu.2013.77
-
The role of high-throughput technologies in clinical cancer genomics.
Expert review of molecular diagnostics 2013;13;2;167-81
PUBMED: 23477557; DOI: 10.1586/erm.13.1
-
Histone deacetylase 1 and 2 are essential for normal T-cell development and genomic stability in mice.
Blood 2013;121;8;1335-44
PUBMED: 23287868; DOI: 10.1182/blood-2012-07-441949
-
Detection of cytoplasmic nucleophosmin expression by imaging flow cytometry.
Cytometry. Part A : the journal of the International Society for Analytical Cytology 2012;81;10;896-900
PUBMED: 22968966; DOI: 10.1002/cyto.a.22116
-
Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice.
Nature genetics 2011;43;5;470-5
PUBMED: 21441929; PMC: 3084174; DOI: 10.1038/ng.796
-
PiggyBac transposon mutagenesis: a tool for cancer gene discovery in mice.
Science (New York, N.Y.) 2010;330;6007;1104-7
PUBMED: 20947725; DOI: 10.1126/science.1193004
-
The use of DNA transposons for cancer gene discovery in mice.
Methods in enzymology 2010;477;91-106
PUBMED: 20699138; DOI: 10.1016/S0076-6879(10)77006-3
-
New approaches for modelling sporadic genetic disease in the mouse.
Disease models & mechanisms 2009;2;9-10;446-53
PUBMED: 19726804; PMC: 2737055; DOI: 10.1242/dmm.001644
-
An acquired translocation in JAK2 Val617Phe-negative essential thrombocythemia associated with autosomal spread of X-inactivation.
Haematologica 2006;91;8;1100-4
PUBMED: 16885051
-
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.
Lancet 2005;366;9501;1945-53
PUBMED: 16325696; DOI: 10.1016/S0140-6736(05)67785-9
-
L3mbtl, the mouse orthologue of the imprinted L3MBTL, displays a complex pattern of alternative splicing and escapes genomic imprinting.
Genomics 2005;86;4;489-94
PUBMED: 16081246; DOI: 10.1016/j.ygeno.2005.06.012
-
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.
Lancet 2005;365;9464;1054-61
PUBMED: 15781101; DOI: 10.1016/S0140-6736(05)71142-9
-
Imprinting of the human L3MBTL gene, a polycomb family member located in a region of chromosome 20 deleted in human myeloid malignancies.
Proceedings of the National Academy of Sciences of the United States of America 2004;101;19;7341-6
PUBMED: 15123827; PMC: 409920; DOI: 10.1073/pnas.0308195101

